Sage Journals: Discover world-class research

Retricted access

Research article

First published 2015-9

A new cognitive rehabilitation programme for patients with multiple sclerosis: the ‘MS-line! Project’

Jordi Gich, Jordi Freixenet, Rafael Garcia [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2015-9

A randomized,controlled,single-blind,6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis

Jordi Gich, Jordi Freixanet, Rafael García [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2020-7

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Oscar Fernández, Guillermo Izquierdo, Eduardo Aguera [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2005-4

On-Line Solid Phase Extraction Using the Prospekt-2 Coupled with a Liquid Chromatography/Tandem Mass Spectrometer for the Determination of Dextromethorphan,Dextrorphan and Guaifenesin in Human Plasma

Debbie L. Kuhlenbeck, Thomas H. Eichhold, Steven H. Hoke [...]

European Journal of Mass Spectrometry

Retricted access

Research article

First published 2019-3

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre,Italian,retrospective,observational study

Damiano Baroncini, Mauro Zaffaroni, Lucia Moiola [...]

Multiple Sclerosis Journal

Retricted access

Other

First published 2026

Should autologous HSCT be a first-line option in highly active MS? No

Karlo Toljan, Anu Jacob

Multiple Sclerosis Journal

Free access

Research article

First published 2014-2

Global Long Interspersed Nuclear Element 1 DNA Methylation in a Colombian Sample of Patients With Late-Onset Alzheimer’s Disease

Hernán G. Hernández, María F. Mahecha, Adriana Mejía [...]

American Journal of Alzheimer's Disease & Other Dementias®

Open access

Other

First published 2026

Should autologous HSCT be a first-line option in highly active MS? Commentary

Anna Karin Hedström

Multiple Sclerosis Journal

Retricted access

Other

First published 2026

Should autologous HSCT be a first-line option in highly active MS: YES

Alice Mariottini, Paolo A Muraro

Multiple Sclerosis Journal

Retricted access

Research article

First published 2016-9

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO

Per Soelberg Sorensen

Multiple Sclerosis Journal

Search results